Compagnie Lombard Odier SCmA’s Stemline Therapeutics, Inc. STML Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-60,500	Closed	-$647K	–	871
2016 Q4	$647K	Hold	60,500	–	–	0.02%	295
2016 Q3	$655K	Hold	60,500	–	–	0.02%	316
2016 Q2	$409K	Hold	60,500	–	–	0.01%	369
2016 Q1	$282K	Hold	60,500	–	–	0.01%	433
2015 Q4	$382K	Hold	60,500	–	–	0.01%	357
2015 Q3	$534K	Hold	60,500	–	–	0.02%	264
2015 Q2	$712K	Buy	60,500 +37,700	+165%	+$523K	0.03%	256
2015 Q1	$330K	Hold	22,800	–	–	0.01%	381
2014 Q4	$389K	Hold	22,800	–	–	0.02%	303
2014 Q3	$284K	Buy	+22,800	New	+$281K	0.01%	431

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Compagnie Lombard Odier SCmA's STML Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Stemline Therapeutics, Inc. (STML) in Q1 2017, closing a stake of 60,500 shares — an estimated $647K sold.

Compagnie Lombard Odier SCmA first reported a position in STML in Q3 2014 and held it in 10 quarters. The position peaked at $712K in Q2 2015. 75 funds tracked by Wall St. Rank hold STML as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining Stemline Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 60,500 Stemline Therapeutics, Inc. shares in Q1 2017, an estimated $647K.
Compagnie Lombard Odier SCmA first reported a position in Stemline Therapeutics, Inc. in Q3 2014 and held it in 10 quarters.
Compagnie Lombard Odier SCmA's Stemline Therapeutics, Inc. position peaked at $712K in Q2 2015.
75 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.